Mendelian randomisation, triglycerides, and CHD

The Lancet

Volumn 375, Issue 9726, 2010, Pages 1584-1586

  Pare, Guillaume ^a   Anand, Sonia S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RANDOMIZATION; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77951816751     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60659-9     Document Type: Note

References (12)

1. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375 (2010) 1634-1639
2. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-508
3. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009) 1993-2000
4. Frick M.H., Elo O., Haapa K.J., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
5. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1894-1961
6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010) 1563-1574
7. Davey S.G., and Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol 32 (2003) 1-22
8. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
9. Lai C.Q., Demissie S., Cupples L.A., et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J Lipid Res 45 (2004) 2096-2105
10. Davey S.G., Ebrahim S., Lewis S., Hansell A.L., Palmer L.J., and Burton P.R. Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 366 (2005) 1484-1498
11. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., and Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119 (2009) 931-999
12. McQueen M.J., Hawken S., Wang X., et al., for the INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372 (2008) 224-233